This study aimed to quantify the expression levels of four EBV-miRNAs (ebv-miR-BHRF1-2-5p, BHRF1-3, BART1-3p, and BART2-5p) in peripheral blood and to explore their possible diagnostic value in distinguishing lymphoma patients from healthy individuals.<h4>Methodology</h4>This case control study included 50 newly diagnosed lymphoma patients (22 Hodgkin lymphoma, 28 Non-Hodgkin lymphoma) and 50 healthy controls recruited in 2025 at the Department of Internal Medicine (Hematology), Atatürk University. This evidence concerns the gene ARL2BP and Hodgkins lymphoma.